The MEA proton therapy market size surpassed USD 70 million in 2025 and is predicted to reach around USD 246.17 million by 2035, registering a CAGR of 13.4% from 2026 to 2035. The market growth is fueled by rising demand for precise cancer therapy and increased investments in healthcare infrastructure.

MEA Proton Therapy Market Statical Scope

The Middle East proton therapy market is gradually expanding as governments strengthen oncology infrastructure and advance hospitals to provide better treatments. Countries, including Saudi Arabia and the UAE, are increasing healthcare spending to improve access to specialized cancer therapies.

Market trends include public -private partnerships, collaborations with international oncology institutions, and investment in workforce training programs. Healthcare providers are focusing on high-quality cancer care delivery while building long-term capabilities in precision radiation therapy technologies.

MEA Proton Therapy Market Share, By Procedure, 2025 (%)

• Services - Services dominate with 30%, covering the necessary installation, maintenance, and technical support services that ensure proton therapy systems remain operational and effective in clinical environments.
• Software - Software holds a significant portion, with a share of 25% of the market, enabling advanced treatment planning, patient data management, and integration with other healthcare technologies to streamline workflow and enhance clinical outcomes.
• Modulators - Modulators hold a smaller share of 10%, as they are critical for controlling and adjusting the intensity of the proton beams to optimize treatment and provide precise radiation doses to the tumor.

MEA Proton Therapy Market Share, By Components, 2025 (%)

• Proton Accelerator - Proton Accelerator dominate with 41%, because it is essential for the proton generation process, accelerating protons to high energies needed for effective cancer treatment in proton therapy systems.
• Cyclotrons - Cyclotrons hold a significant share of 15% of the market, offering a reliable, cost-effective proton acceleration option, particularly for smaller and mid-sized proton therapy systems.
• Synchrocyclotrons – Synchrocyclotrons hold a smaller share of 9 %of the market, offering a compact and affordable proton acceleration solution, ideal for smaller-scale proton therapy systems.

MEA Proton Therapy Market Share, By Type, 2025 (%)

• Rotating Proton Therapy Systems - Rotating Proton Therapy Systems dominate with 60% of the market, as they provide the flexibility to deliver proton therapy from multiple angles, ensuring precise and targeted treatment, particularly for complex tumours.
• Non-Rotating Proton Therapy Systems - Non-Rotating Proton Therapy Systems hold a significant share of 40%, offering a cost-effective alternative for facilities with lower treatment demands or smaller-scale operations, though lacking the flexibility of rotating systems.

MEA Proton Therapy Market Share, By Set-Up Systems, 2025 (%)

• Multi-Room Systems - Multi-Room Systems represent 60% of the market, as they allow multiple patients to be treated simultaneously, thus improving throughput and efficiency in larger medical centers and hospitals.
• Single-Room Systems - Single-Room Systems hold a significant portion, with a share of 40%, due to lower installation costs and space requirements. These systems are preferred by smaller or specialized facilities offering a more compact and cost-effective solution.

MEA Proton Therapy Market Share, By Applications, 2025 (%)

• Pediatric Cancer - Pediatric Cancer leads the segment, with a share of 26%, driven by the growing use of proton therapy in pediatric cancer treatments due to its precision in targeting tumours.
• Prostate Cancer - Prostate Cancer holds a significant portion, with a share of 20%, supported by the ability to deliver highly targeted treatment to prostate tumours, reducing the risk of side effects and damage to surrounding sensitive organs such as the bladder and rectum.

MEA Proton Therapy Market Share, By End Use, 2025 (%)

• Hospitals - Hospitals dominate with 50% of the market share, driven by integrated oncology departments and advanced radiotherapy infrastructure. Large hospitals have the ability to handle large patient volumes and provide specialised treatments.
• Cancer Research Institutes - Cancer Research Institutes hold 30% of the market, driven by the significant role these institutions play in advancing proton therapy technologies, conducting clinical trials, and exploring new therapeutic applications, which are essential for the ongoing development of proton therapy.
• Ambulatory Surgical Centres - Ambulatory Surgical Centres account for 20% of the market, providing outpatient care and offering patients a convenient alternative for receiving proton therapy treatment without the need for an overnight hospital stay, making it an attractive option for certain patient groups.

Competitive Landscape

Key players in the proton therapy market include Varian Medical Systems, Inc., Hitachi, Ltd., IBA (Ion Beam Applications), Sumitomo Heavy Industries, Ltd., and Mevion Medical Systems. IBM is a dominant global provider in the proton therapy market. Mevion Medical Systems is known for providing radiotherapy and proton therapy systems. Sumitomo Heavy Industries provides high-energy, heavy-ion, and proton therapy systems.

Segments Covered in the Report

By Procedure

• Accelerators (Cyclotrons, Synchrotrons)
• Beam Delivery (Pencil Beam Scanning, Passive Scattering, Uniform Scanning)
• Modulators
• Software
• Services

By Components

• Proton Accelerator
• Cyclotrons
• Synchrotrons
• Synchrocyclotrons
• Linacs
• H-Minus Synchrotrons
• Separated Sector Cyclotrons

By Type

• Rotating Proton Therapy Systems
• Non-Rotating Proton Therapy Systems

By Set-Up Systems

• Multi-Room Systems
  Single-Room Systems

By Applications

• Pediatric Cancer
• Prostate Cancer
• Head and Neck Cancer
• Breast Cancer
• Lung Cancer

By End Use

• Hospitals
• Cancer Research Institutes
• Ambulatory Surgical Centres